Original Article

You have full text access to this OnlineOpen article

Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain†

High rate of thromboembolic events (CALGB 500102)

  1. Susan E. Krown MD1,¶,*,
  2. Donna Niedzwiecki PhD2,
  3. Wen-Jen Hwu PhD, MD1,‡,‖,
  4. Lydia Hodgson MS2,
  5. Alan N. Houghton MD1,
  6. Frank G. Haluska MD, PhD3,§,††,
  7. for the Cancer and Leukemia Group B‡‡

Article first published online: 19 SEP 2006

DOI: 10.1002/cncr.22239

Issue

Cancer

Cancer

Volume 107, Issue 8, pages 1883–1890, 15 October 2006

Additional Information

How to Cite

Krown, S. E., Niedzwiecki, D., Hwu, W.-J., Hodgson, L., Houghton, A. N., Haluska, F. G. and for the Cancer and Leukemia Group B (2006), Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain. Cancer, 107: 1883–1890. doi: 10.1002/cncr.22239

Author Information

  1. 1

    Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

  2. 2

    CALGB Statistical Center, Duke University Medical Center, Durham, North Carolina

  3. 3

    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts

  1. ‡

    Department of Melanoma Medical Oncology, Department of Medicine, University of Texas, M. D. Anderson Cancer Center, Houston, Texas

  2. §

    Tufts-New England Medical Center, Boston, Massachusetts

  1. Fax: (212) 717-3342

  2. ‖

    Dr. Hwu has served as a consultant to Schering-Plough, the manufacturer of temozolomide, and has received honoraria from Schering-Plough and from Celgene, the manufacturer of thalidomide.

  3. ††

    Dr. Haluska has served as a consultant to Schering-Plough, received honoraria from Schering-Plough, and provided expert testimony concerning temozolomide.

  4. ‡‡

    The following institutions participated in this study: CALGB Statistical Center, Durham, NC (Stephen George, PhD, supported by CA33601); Christiana Care Health Services, CCOP, Wilmington, DE (Stephen Grubbs, MD, supported by CA45418); Duke University Medical Center, Durham, NC (Jeffrey Crawford, MD, supported by CA47577); Georgetown University Medical Center, Washington, DC (Edward Gelmann, MD, supported by CA77597); Massachusetts General Hospital, Boston, MA (Michael L. Grossbard, MD, supported by CA12449); Memorial Sloan-Kettering Cancer Center, New York, NY (Clifford Hudis, MD, supported by CA77651); Mount Sinai Medical Center, Miami, FL (Rogerio Lilenbaum, MD, supported by CA45564); Rhode Island Hospital, Providence, RI (William Sikov, MD, supported by CA08025); Southeast Cancer Control Consortium, CCOP, Goldsboro, NC (James N. Atkins, MD, supported by CA45808); University of Chicago, Chicago, IL (Gini Fleming, MD, supported by CA41287); University of Iowa, Iowa City, IA (Gerald Clamon, MD, supported by CA47642); University of Missouri/Ellis Fischel Cancer Center, Columbia, MO (Michael C Perry, MD, supported by CA12046); and University of North Carolina at Chapel Hill, Chapel Hill, NC (Thomas C. Shea, MD, supported by CA47559).

*Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021

  1. †

    The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.

Publication History

  1. Issue published online: 3 OCT 2006
  2. Article first published online: 19 SEP 2006
  3. Manuscript Accepted: 9 AUG 2006
  4. Manuscript Revised: 20 JUL 2006
  5. Manuscript Received: 9 MAY 2006

Funded by

  • National Cancer Institute. Grant Numbers: (CA31946), (CA77651), (CA33601), CA12449)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (108K)

REFERENCES

  • 1
    Hwu W-J, Lis E, Menell JH, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma. A phase II study. Cancer. 2005; 103: 2590–2597.
    Direct Link:
  • 2
    Koc M, McGregor J, Grecula J, Bauer CJ, Gupta N, Gahbauer RA. Gamma knife radiosurgery for intracranial metastatic melanoma: an analysis of survival and prognostic factors. J Neurooncol. 2005; 71: 307–313.
  • 3
    Meier S, Baumert BG, Maier T, et al. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie. 2004; 27: 145–149.
  • 4
    Agarwala SS, Reyderman L, Statkevich P, et al. Pharmacokinetic study of temozolomide penetration into CSF in a patient with dural melanoma. Ann Oncol. 1998; 9( Suppl 4): 138. Abstract 659a.
  • 5
    Stupp R, Ostermann S, Leyvraz S, Csajka C, Buclin T, Decosterd LA. Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration. Proc Am Soc Clin Oncol. 2001; 20: 59a. Abstract.
  • 6
    Yung WKA, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999; 17: 2762–2771.
  • 7
    Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004; 22: 2101–2107.
  • 8
    Bafaloukos D, Tsoutsos D, Fountzilas G, et al. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Res. 2004; 14: 289–294.
  • 9
    Paul MJ, Summers Y, Calvert AH, et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res. 2002; 12: 175–178.
  • 10
    Atkins MB, Gollob JA, Sosman JA, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2 and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res. 2002; 8: 3075–3081.
  • 11
    Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998; 58: 4363–4367.
  • 12
    Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003; 88: 1004–1011.
  • 13
    Gander M, Leyvraz S, Decosterd L, et al. Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol. 1999; 10: 831–838.
  • 14
    Hwu W-J, Krown SE, Panageas KS, et al. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol. 2002; 20: 2610–2615.
  • 15
    D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994; 91: 4082–4085.
  • 16
    Hwu W-J, Krown SE, Menell JH, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol. 2003; 21: 3351–3356.
  • 17
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205–216.
  • 18
    Bick RL. Cancer-associated thrombosis [editorial]. N Engl J Med. 2003; 349: 109–111.
  • 19
    Lee AYY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003; 107: I17–I21.
  • 20
    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ3rd. Risk factors for deep vein thrombosis and pulmonary embolism. A population-based case-control study. Arch Intern Med. 2000; 160: 809–815.
  • 21
    Lee AY. Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treat Rev. 2002; 28: 137–140.
  • 22
    Gerber DE, Grossman SA, Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol. 2006; 24: 1310–1318.
  • 23
    Numico G, Garrone O, Dongiovanni V, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer. 2005; 103: 994–999.
    Direct Link:
  • 24
    Weijl NI, Rutten MFJ, Zwinderman AH, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000; 18: 2169–2178.
  • 25
    Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998; 160: 2021–2124.
  • 26
    Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988; 318: 404–407.
  • 27
    Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer.National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 1996; 14: 2731–2737.
  • 28
    Clahsen PC, van de Velde CJ, Julien JP, Floiras JL, Mignolet FY. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol. 1994; 12: 1266–1271.
  • 29
    Rivkin SE, Green S, Metch B, et al. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1994; 12: 2078–2085.
  • 30
    Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991; 9: 286–294.
  • 31
    Weiss RB, Tormey DC, Holland JF, Weinberg VE. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep. 1981; 65: 677–679.
  • 32
    Wall JG, Weiss RB, Norton L, et al. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a Cancer and Leukemia Group B Study. Am J Med. 1989; 87: 501–504.
  • 33
    von Tempelhoff GF, Dietrich M, Hommel G, Heilmann L. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol. 1996; 14: 2560–2568.
  • 34
    Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer. 1984; 54: 1264–1268.
    Direct Link:
  • 35
    Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999; 341: 1565–1571.
  • 36
    Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001; 98: 492–494.
  • 37
    Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep vein thrombosis in multiple myeloma patients receiving thalidomide in combination with chemotherapy. Blood. 2001; 98: 1614–1615.
  • 38
    Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002; 100: 1168–1171.
  • 39
    Urbauer E, Kaufmann H, Nosslinger T, Raderer M, Drach J. Thromboembolic events during treatment with thalidomide. Blood. 2002; 99: 4247–4248.
  • 40
    Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma [letter]. N Engl J Med. 2001; 344: 1951–1952.
  • 41
    Desai AA, Vogelzang NJ, Rini BI, et al. A phase II trial of weekly intravenous gemcitabine with prolonged continuous infusion fluorouracil and oral thalidomide in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 2001; 20: 2448. Abstract.
  • 42
    Figg W, Arlen P, Gulley J, et al. A randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. Semin Oncol. 2001; 28( Suppl): 62S–66S.
  • 43
    Fine HA, Wen PY, Maher EA, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol. 2003; 21: 2299–2304.
  • 44
    Zangari M, Saghafifar F, Anaissie E, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 2002; 13: 187–192.
  • 45
    Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004; 126: 715–721.
    Direct Link:
  • 46
    Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer. 1994; 73: 493–498.
    Direct Link:
  • 47
    Levin JM, Schiff D, Loeffler JS, Fine HA, Black PM, Wen PY. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology. 1993; 43: 1111–1114.
  • 48
    Knovich MA, Lesser GJ. The management of thromboembolic disease in patients with central nervous system malignancies. Curr Treat Options Oncol. 2004; 5: 511–517.
View Full Article (HTML) Get PDF (108K)